Program
Anti-CTLA-4 Monoclonal Antibody SHR-8068
Also written as “SHR-8068 Injection”, “SHR-8068” and “SHR-8068 + Adebrelimab + Bevacizumab”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Hepatocellular · Colorectal Neoplasms · Carcinoma, Renal Cell · Rectal Neoplasms, led by Jiangsu HengRui Medicine.
Drug pageAnti-CTLA-4 Monoclonal Antibody SHR-8068: every studyAll 17 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 1615 open or running | phase 3since Mar 21, 2024 | May 27, 2022 | Jul 2027phase 2 · NCT07682272 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since May 27, 2022.
- Mar 21, 2024Phase 3 study in Non-squamous Non-small Cell Lung CancerNCT06335355 · 401 planned · China
- May 23, 2024Phase 2 study in Advanced Non-small Cell Lung CancerNCT06434103
- Sep 6, 2024Phase 2 study in Carcinoma, Non-Small-Cell LungNCT06589778 · 124 planned · China
- Sep 26, 2024Phase 3 study in Advanced Hepatocellular CarcinomaNCT06618664 · 590 planned · China
- Jul 8, 20252 phase 2 studiesNCT07071714, NCT07110571
- Sep 5, 2025Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07170995 · 460 planned · China
- Nov 13, 2025Phase 3 study in Advanced Biliary Tract CancerNCT07229625 · 604 planned · China
- Nov 14, 20252 phase 2 studiesNCT07241767, NCT07239596
- Feb 25, 2026Phase 3 study in Locally Advanced Resectable Rectal CancerNCT07454720 · 165 planned · China
- Jun 26, 2026Phase 2 study in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskNCT07682272 · 120 planned · China
- Jul 2, 2026Phase 3 study in Carcinoma, HepatocellularNCT07691762 · 690 planned · China
- Jul 10, 2026Phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645 · 180 planned · China
- Sep 25, 2026Primary completion moved from 2026-09 to 2026-10Date moved laterphase 3 · +1 months · NCT06618664
- Oct 29, 2026Primary completion moved from 2031-04 to 2031-09Date moved laterphase 3 · +5 months · NCT07691762
Ahead
- Jul 2027Primary completion: phase 2 study in Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskNCT07682272
- Nov 2027Primary completion: phase 2 study in Lung NeoplasmsNCT07241767
- Jun 2028Primary completion: phase 2 study in Resectable Non-small Cell Lung CancerNCT07704645
- Oct 2028Primary completion: phase 3 study in Non-squamous Non-small Cell Lung CancerNCT06335355
TargetBeta
“A monoclonal antibody directed against the human T-cell-expressed receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4; CTLA4; CD152), ”NCIt, by rule
Other programs on CTLA4
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tremelimumabrule | AstraZeneca | phase 3 | 47 |
| cadonilimabrule | Akeso | phase 3 | 45 |
| Iparomlimab/Tuvonralimabrule | Qilu Pharmaceutical | phase 3 | 22 |
| volrustomig | AstraZeneca | phase 3 | 19 |
| erfonrilimabrule | Alphamab Oncology | phase 3 | 14 |
| Anti-CTLA-4 Monoclonal Antibody IBI310rule | Innovent Biologics | phase 3 | 11 |
| gotistobartrule | oncoc4-inc | phase 3 | 5 |
| zalifrelimabrule | Agenus | phase 2 | 6 |
| porustobartrule | harbour-biomed-guangzhou-co-ltd | phase 2 | 5 |
| lorigerlimabrule | MacroGenics | phase 2 | 4 |
| Anti-PD-1/Anti-CTLA-4/Anti-VEGF Trispecific Antibody HC010rule | hc-biopharma-inc | phase 2 | 2 |
| GB268rule | eddingpharm-zhuhai-co-ltd | phase 2 | 2 |
Studies
All 16 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07704645Resectable Non-small Cell Lung Cancer · China | 2 | Not yet recruiting | Jun 2028 | 180 |
| NCT07691762Carcinoma, Hepatocellular · China | 3 | Not yet recruiting | Sep 2031 | 690 |
| NCT07682272Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence Risk · China | 2 | Not yet recruiting | Jul 2027 | 120 |
| NCT07454720Locally Advanced Resectable Rectal Cancer · China | 3 | Recruiting | Nov 2032 | 165 |
| NCT07239596Advanced Renal Cell Carcinoma · China | 2 | Recruiting | Dec 2030 | 92 |
| NCT07241767Lung Neoplasms · China | 2 | Recruiting | Nov 2027 | 200 |
| NCT07229625Advanced Biliary Tract Cancer · China | 3 | Recruiting | Dec 2029 | 604 |
| NCT07170995Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Dec 2030 | 460 |
| NCT07110571Stomach Neoplasms · China | 2 | Recruiting | Aug 2026 | 200 |
| NCT07071714Colorectal Neoplasms · China | 2 | Active, not recruiting | Oct 2031 | 103 |
| NCT06618664Advanced Hepatocellular Carcinoma · China | 3 | Recruiting | Oct 2026 | 590 |
| NCT06589778Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Apr 30, 2026 | 124 |
| NCT06434103Advanced Non-small Cell Lung Cancer | 2 | Withdrawn | Oct 10, 2024 | 0 |
| NCT06335355Non-squamous Non-small Cell Lung Cancer · China | 3 | Not yet recruiting | Oct 2028 | 401 |
| NCT06247956Esophageal Squamous Cell Carcinoma · China | 2 | Active, not recruiting | Dec 30, 2025 | 153 |
| NCT05416775Advanced Non-small Cell Lung Cancer · China | 2 | Recruiting | Jun 30, 2026 | 168 |
How it is read
Names in the registry
- “SHR-8068 Injection”, 4 entries
- “SHR-8068”, 2 entries
- “SHR-8068 + Adebrelimab + Bevacizumab”, 1 entry
- “SHR-8068;Adebrelimab ;Bevacizumab”, 1 entry
- “SHR-8068 ; SHR-4610”, 1 entry
Codes read as this program: SHR8068.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 6 studies
- Carcinoma, Hepatocellular, 3 studies
- Colorectal Neoplasms, 1 study
- Carcinoma, Renal Cell, 1 study
- Rectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.